Alison Nankervis

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 600 citations · Full text

Metabolic Syndrome, Diabetes Management, Urology +10

Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial

John R. Petrie, Nish Chaturvedi, Ian Ford et al. · The Lancet Diabetes & Endocrinology · 2017 · 337 citations · Full text

Metabolic Syndrome, Type 1, Diabetes Management +7

ADIPS Consensus Guidelines for the Testing and Diagnosis of Gestational Diabetes Mellitus in Australia

Alison Nankervis, David McIntyre, Robert G. Moses et al. · 2014 · 100 citations

Medicine, Diabetes, Pediatrics +7

Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real‐life experience from a tertiary hospital

Zanariah Hussein, John M. Wentworth, Alison Nankervis et al. · The Medical Journal of Australia · 2004 · 90 citations